-
Je něco špatně v tomto záznamu ?
Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project
J. Secnik, M. Eriksdotter, H. Xu, M. Annetorp, SweGeroCOVID Project, A. Rytarowski, K. Johnell, S. Hägg, D. Religa
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu pozorovací studie, časopisecké články, práce podpořená grantem
NLK
BioMedCentral
od 2009-06-01
BioMedCentral Open Access
od 2009
Directory of Open Access Journals
od 2009
Free Medical Journals
od 2009
PubMed Central
od 2009
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
Springer Nature OA/Free Journals
od 2009-06-01
- MeSH
- antipsychotika * terapeutické užití MeSH
- COVID-19 * MeSH
- lidé MeSH
- následná péče MeSH
- propuštění pacienta MeSH
- psychotropní léky terapeutické užití MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
BACKGROUND: Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia and medication use with mortality in the hospitalized and discharged patients who suffered from COVID-19. METHODS: We conducted an open-cohort observational study based on electronic patient records from nine geriatric care clinics in the larger Stockholm area, Sweden, between February 28, 2020, and November 22, 2021. In total, we identified 5122 hospitalized patients diagnosed with COVID-19, out of which 762 (14.9%) patients had concurrent dementia and 4360 (85.1%) were dementia-free. Patients' age, sex, baseline oxygen saturation, comorbidities, and medication prescription (cardiovascular and psychotropic medication) were registered at admission. The hazard ratios (HRs) with 95% confidence intervals (CIs) of in-hospital, 30-day, 90-day, 365-day post-discharge, and overall mortality during the follow-up were obtained. Then, the associations of dementia and medication use with mortality were determined using proportional hazards regression with time since entry as a time scale. RESULTS: After adjustment, dementia was independently associated with 68% higher in-hospital mortality among COVID-19 patients compared to patients who were dementia-free at admission [HRs (95% CI) 1.68 (1.37-2.06)]. The increase was consistent post-discharge, and the overall mortality of dementia patients was increased by 59% [1.59 (1.40-1.81)]. In addition, the prescription of antipsychotic medication at hospital admission was associated with a 70% higher total mortality risk [1.70 (1.47-1.97)]. CONCLUSIONS: The clinical co-occurence of dementia and COVID-19 increases the short- and long-term risk of death, and the antipsychotics seem to further the risk increase. Our results may help identify high-risk patients in need of more specialized care when infected with COVID-19.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004642
- 003
- CZ-PrNML
- 005
- 20230425171635.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13195-022-01154-w $2 doi
- 035 __
- $a (PubMed)36609457
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Secnik, Juraj $u Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Neo, Blickagången 16, 14152, Huddinge, Sweden. juraj.secnik@ki.se $u Department of Neurology, Charles University, Second Faculty of Medicine, Motol University Hospital, Prague, Czech Republic. juraj.secnik@ki.se
- 245 10
- $a Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project / $c J. Secnik, M. Eriksdotter, H. Xu, M. Annetorp, SweGeroCOVID Project, A. Rytarowski, K. Johnell, S. Hägg, D. Religa
- 520 9_
- $a BACKGROUND: Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia and medication use with mortality in the hospitalized and discharged patients who suffered from COVID-19. METHODS: We conducted an open-cohort observational study based on electronic patient records from nine geriatric care clinics in the larger Stockholm area, Sweden, between February 28, 2020, and November 22, 2021. In total, we identified 5122 hospitalized patients diagnosed with COVID-19, out of which 762 (14.9%) patients had concurrent dementia and 4360 (85.1%) were dementia-free. Patients' age, sex, baseline oxygen saturation, comorbidities, and medication prescription (cardiovascular and psychotropic medication) were registered at admission. The hazard ratios (HRs) with 95% confidence intervals (CIs) of in-hospital, 30-day, 90-day, 365-day post-discharge, and overall mortality during the follow-up were obtained. Then, the associations of dementia and medication use with mortality were determined using proportional hazards regression with time since entry as a time scale. RESULTS: After adjustment, dementia was independently associated with 68% higher in-hospital mortality among COVID-19 patients compared to patients who were dementia-free at admission [HRs (95% CI) 1.68 (1.37-2.06)]. The increase was consistent post-discharge, and the overall mortality of dementia patients was increased by 59% [1.59 (1.40-1.81)]. In addition, the prescription of antipsychotic medication at hospital admission was associated with a 70% higher total mortality risk [1.70 (1.47-1.97)]. CONCLUSIONS: The clinical co-occurence of dementia and COVID-19 increases the short- and long-term risk of death, and the antipsychotics seem to further the risk increase. Our results may help identify high-risk patients in need of more specialized care when infected with COVID-19.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a následná péče $7 D000359
- 650 _2
- $a propuštění pacienta $7 D010351
- 650 _2
- $a psychotropní léky $x terapeutické užití $7 D011619
- 650 12
- $a antipsychotika $x terapeutické užití $7 D014150
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Eriksdotter, Maria $u Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Neo, Blickagången 16, 14152, Huddinge, Sweden $u Theme Aging, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Xu, Hong $u Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Neo, Blickagången 16, 14152, Huddinge, Sweden $u Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Annetorp, Martin $u Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Neo, Blickagången 16, 14152, Huddinge, Sweden
- 700 1_
- $a Rytarowski, Aleksander $u Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Neo, Blickagången 16, 14152, Huddinge, Sweden
- 700 1_
- $a Johnell, Kristina $u Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Hägg, Sara $u Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Religa, Dorota $u Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Neo, Blickagången 16, 14152, Huddinge, Sweden $u Theme Aging, Karolinska University Hospital, Stockholm, Sweden
- 710 2_
- $a SweGeroCOVID Project
- 773 0_
- $w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 15, č. 1 (2023), s. 5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36609457 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171631 $b ABA008
- 999 __
- $a ok $b bmc $g 1924998 $s 1190851
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 15 $c 1 $d 5 $e 20230106 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
- LZP __
- $a Pubmed-20230418